IPO - Drugs Made In America Acquisition Corp.

Form Type: 8-K

Filing Date: 2025-02-25

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025016702

Filing Summary: On February 18, 2025, Drugs Made In America Acquisition Corp. reported the consummation of its initial public offering (IPO), which involved the sale of 20,000,000 units at a price of $10.00 per unit, generating gross proceeds of $200,000,000. Each unit consists of one ordinary share and one right to receive one-eighth of an ordinary share following an initial business combination. The underwriters were granted a 45-day option to purchase an additional 3,000,000 units, which they exercised fully, resulting in an additional 3,000,000 units sold, producing an extra $30,000,000. Together, these transactions led to total gross proceeds of $231,150,000, which have been placed in a trust account for public shareholders. The Company also completed a private placement of 400,000 units for $4,000,000, with some funds still pending. A pro-forma balance sheet reflecting these financial activities is attached as Exhibit 99.1.

Document Link: View Document

Form Type: 8-K

Filing Date: 2025-02-04

Corporate Action: Ipo

Type: New

Accession Number: 000121390025010079

Filing Summary: On January 29, 2025, Drugs Made In America Acquisition Corp. completed its initial public offering (IPO) of 20,000,000 units, each unit comprising one Ordinary Share and one right to receive one-eighth of an Ordinary Share upon the consummation of a business combination. The units were sold at $10.00 each, generating aggregate gross proceeds of $200,000,000. Additionally, the Company executed a private placement with its sponsor, purchasing 400,000 private units for $4,000,000. As of January 29, 2025, a total of $201,000,000 from the IPO and Private Placement was deposited into a trust account for the public shareholders' benefit.

Document Link: View Document

Form Type: 8-K

Filing Date: 2025-01-30

Corporate Action: Ipo

Type: New

Accession Number: 000121390025008377

Filing Summary: On January 27, 2025, Drugs Made In America Acquisition Corp. filed a Form 8-K to report the effectiveness of its registration statement relating to an initial public offering (IPO) of 20,000,000 units at an offering price of $10.00 per unit, generating gross proceeds of $200,000,000. The registration statement was declared effective on January 7, 2025, with a post-effective amendment declared effective on January 27, 2025. The Company established a trust account to hold the proceeds, totaling $201,000,000. Coinciding with the IPO, a private placement of 400,000 units occurred, generating additional proceeds of $4,000,000. Various agreements, including an Underwriting Agreement and a Rights Agreement, were entered into in connection with the IPO. The document also notes the adoption of a Second Amended and Restated Memorandum and Articles of Association on January 7, 2025, and includes announcements related to the pricing and closing of the IPO as press releases.

Document Link: View Document

Form Type: 424B4

Filing Date: 2025-01-29

Corporate Action: Ipo

Type: New

Accession Number: 000121390025007724

Filing Summary: Drugs Made In America Acquisition Corp. is a newly incorporated blank check company established in the Cayman Islands, aiming to raise $200 million through an IPO of 20 million units at an offering price of $10.00 each. The company has not yet identified a business combination target but intends to focus its search within the pharmaceutical industry. Each unit offered consists of one ordinary share and one right to receive one-eighth of an ordinary share upon successful business combination completion. The offering allows shareholders to redeem shares at a price calculated based on the amount held in the trust account if the business combination is completed, with restrictions applied to shareholders holding more than 15% of the offering. The prospectus includes their intention to extend the completion window for the business combination up to 21 months under certain conditions if necessary. A commitment of 400,000 units in a private placement is noted alongside interests from non-managing sponsor investors, who may influence investor dynamics. The prospectus also highlights potential dilution for public shareholders due to the nominal acquisition cost of founder shares by the sponsor. The company has been approved for listing on Nasdaq under the symbol 'DMAAU'. The underwriters are responsible for facilitating this offering, and the company emphasizes risks associated with such investments.

Document Link: View Document

Form Type: POS AM

Filing Date: 2025-01-14

Corporate Action: Ipo

Type: New

Accession Number: 000121390025003137

Filing Summary: Drugs Made In America Acquisition Corp. filed a Post-Effective Amendment to its registration statement for an initial public offering (IPO) of securities totaling $200 million, consisting of 20 million units priced at $10 each. The company is incorporated in the Cayman Islands and aims to effect a business combination in the pharmaceutical industry. The units comprise one ordinary share and one right to receive one-eighth of an ordinary share upon the consummation of an initial business combination. The filing includes details about the proposed structure of the offering, redemption rights for shareholders, and potential conflicts of interest due to the sponsor's ownership of founder shares at a nominal price. The company plans to list its units on Nasdaq under the symbol 'DMAAU' and is presented as an emerging growth and smaller reporting company with reduced public reporting requirements. The prospectus cautions investors about the risks associated with investing in its securities and indicates the company has not yet engaged with any specific business targets for acquisition.

Document Link: View Document

Form Type: 8-A12B

Filing Date: 2025-01-07

Corporate Action: Ipo

Type: New

Accession Number: 000121390025001726

Filing Summary: Drugs Made In America Acquisition Corp. is registering certain classes of securities, including Ordinary Shares, Rights, and Units. The registration is conducted under Section 12(b) of the Securities Exchange Act of 1934 with the securities expected to be traded on The Nasdaq Stock Market LLC. The ordinary shares are priced at $0.0001 per share, and the rights allow holders to receive one-eighth of an ordinary share. The units consist of one ordinary share and one right to receive an additional one-eighth of an ordinary share. The effective registration follows a previous filing under the Registration Statement on Form S-1 (File No. 333-281170) made on August 1, 2024. No exhibits are required as there are no other securities of the Registrant registered on the exchange. The document is signed by the CEO, Lynn Stockwell, on January 7, 2025.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-01-06

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025001208

Filing Summary: This document is Amendment No. 6 to the Registration Statement on Form S-1 for Drugs Made In America Acquisition Corp., filed with the U.S. Securities and Exchange Commission. The registrant is a Cayman Islands company seeking to go public. The filing indicates that they are registering for a proposed sale to the public, contingent on the effective date of this registration statement. The amendment consists of the facing page, explanatory note, Part II of the registration statement, and the signature page, along with various exhibits detailing underwriting agreements, memorandums, and opinions from legal counsel. The registrant is classified as a non-accelerated filer and an emerging growth company. Amendments pertain to compliance, securities registration, and indemnification undertakings for officers and directors.

Document Link: View Document

Form Type: CORRESP

Filing Date: 2025-01-03

Corporate Action: Ipo

Type: New

Accession Number: 000121390025000703

Filing Summary: Drugs Made In America Acquisition Corp. submitted a request for the acceleration of the effectiveness of their Registration Statement on Form S-1, which is filed under File No. 333-281170. The request aims for the Registration Statement to become effective on January 7, 2025, at 4:00 p.m. Eastern time, or as soon thereafter as possible. The Company acknowledges that the Securities and Exchange Commission's declaration of effectiveness does not exempt it from any future actions by the Commission regarding the Registration Statement and does not lessen the Company's responsibility for the accuracy of disclosures within the Registration Statement. Additionally, the Company indicates that any changes to the acceleration request will be promptly communicated to the SEC, and an oral request for acceleration may be made by an executive officer or an attorney from the Company's counsel, Loeb & Loeb LLP.

Document Link: View Document

Form Type: CORRESP

Filing Date: 2025-01-03

Corporate Action: Ipo

Type: New

Accession Number: 000121390025000704

Filing Summary: Drugs Made In America Acquisition Corp. has filed a request to accelerate the effective date of its Registration Statement on Form S-1, allowing it to become effective at 4:00 p.m. Eastern Time on January 7, 2025. The firm believes this acceleration will facilitate the distribution of its securities and has confirmed compliance with the necessary regulatory requirements, including Rule 15c2-8 under the Securities Exchange Act of 1934. The correspondence is directed to the Securities and Exchange Commission and indicates ongoing coordination with Loeb & Loeb LLP regarding the registration process.

Document Link: View Document